Elevated Capital Advisors’s AbbVie ABBV Stock Holding History

Elevated Capital Advisors’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$993K	Sell	3,945 -2,390	-38%	-$514K	0.27%	82
2026 Q1	$1.38M	Sell	6,335 -3,139	-33%	-$696K	0.35%	69
2025 Q4	$2.16M	Sell	9,474 -3,583	-27%	-$816K	0.5%	49
2025 Q3	$3.02M	Buy	13,057 +650	+5%	+$132K	0.75%	34
2025 Q2	$2.6M	Hold	12,407	–	–	0.73%	33
2025 Q1	$2.6M	Sell	12,407 -682	-5%	-$133K	0.73%	33
2024 Q4	$2.33M	Buy	13,089 +1,377	+12%	+$253K	0.63%	35
2024 Q3	$2.31M	Buy	11,712 +1,995	+21%	+$372K	0.61%	36
2024 Q2	$1.67M	Sell	9,717 -8,988	-48%	-$1.49M	0.47%	58
2024 Q1	$3.41M	Buy	18,705 +324	+2%	+$55.8K	0.98%	27
2023 Q4	$2.85M	Buy	18,381 +266	+1%	+$38.8K	0.89%	30
2023 Q3	$2.7M	Buy	18,115 +1,131	+7%	+$166K	0.92%	33
2023 Q2	$2.29M	Buy	16,984 +755	+5%	+$111K	0.76%	39
2023 Q1	$2.59M	Buy	16,229 +36	+0.2%	+$5.5K	0.93%	30
2022 Q4	$2.62M	Buy	16,193 +3,019	+23%	+$463K	1%	30
2022 Q3	$1.77M	Buy	+13,174	New	+$1.89M	0.7%	39
2022 Q1	$2.13M	Buy	+13,109	New	+$1.9M	0.7%	38
2021 Q3	$1.36M	Buy	+12,588	New	+$1.44M	0.47%	63
2021 Q1	$1.27M	Buy	11,670 +3,738	+47%	+$400K	0.49%	67
2020 Q4	$850K	Sell	7,932 -734	-8%	-$70.5K	0.37%	91
2020 Q3	$857K	Sell	8,666 -30	-0.3%	-$2.82K	0.4%	90
2020 Q2	$817K	Buy	+8,696	New	+$766K	0.38%	99
2019 Q4	$441K	Buy	+4,981	New	+$414K	0.49%	61
2019 Q1	$827K	Buy	+10,103	New	+$827K	0.55%	59

Other funds holding ABBV

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Elevated Capital Advisors's ABBV Position: Q2 2026 in Review

Elevated Capital Advisors reduced its AbbVie (ABBV) stake by 38% in Q2 2026, selling an estimated $514K and leaving 3,945 shares worth $993K. The position accounts for 0.27% of the portfolio, ranked #82.

Elevated Capital Advisors first reported a position in ABBV in Q1 2019 and has held it in 24 quarters since. The position peaked at $3.41M in Q1 2024. 4,201 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

Elevated Capital Advisors held 3,945 shares of AbbVie worth $993K as of Q2 2026.
Elevated Capital Advisors sold 2,390 AbbVie shares in Q2 2026, an estimated $514K.
AbbVie made up 0.27% of Elevated Capital Advisors's portfolio in Q2 2026, its #82 holding.
Elevated Capital Advisors first reported a position in AbbVie in Q1 2019 and has held it in 24 quarters since.
Elevated Capital Advisors's AbbVie position peaked at $3.41M in Q1 2024.
4,201 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Elevated Capital Advisors's 13F filing for Q2 2026, filed 3 Aug 2026.